VERTEX PHARMACEUTICALS INC / MA OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $4.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2026-06-30 was $4.90M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2026-03-31 was $8.80M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2025-12-31 was $100.00K, a 99.17% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2025-09-30 was -$1.00M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2025 was -$7.60M, a 1366.67% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2024 was $600.00K.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2023 was -$2.70M.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2022 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.90M 10-Q · filed 2026-08-04 | $13.70M 10-Q · filed 2026-08-04 | $13.80M derived: sum of 3 quarters · filed 2026-08-04 | $12.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $8.80M 10-Q · filed 2026-05-05 | $8.90M derived: sum of 2 quarters · filed 2026-05-05 | $7.90M derived: sum of 3 quarters · filed 2026-05-05 | $5.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$900.00K derived: sum of 2 quarters · filed 2026-02-13 | -$3.00M derived: sum of 3 quarters · filed 2026-08-04 | -$7.60M 10-K · filed 2026-02-13 |
| 2025-09-30 | -$1.00M 10-Q · filed 2025-11-04 | -$3.10M derived: sum of 2 quarters · filed 2026-08-04 | -$7.70M 10-Q · filed 2025-11-04 | $4.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$2.10M 10-Q · filed 2026-08-04 | -$6.70M 10-Q · filed 2026-08-04 | $5.30M derived: sum of 3 quarters · filed 2026-08-04 | -$13.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$4.60M 10-Q · filed 2026-05-05 | $7.40M derived: sum of 2 quarters · filed 2026-05-05 | -$10.90M derived: sum of 3 quarters · filed 2026-05-05 | -$9.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$6.30M derived: sum of 2 quarters · filed 2026-02-13 | -$4.80M derived: sum of 3 quarters · filed 2026-02-13 | $600.00K 10-K · filed 2026-02-13 |
| 2024-09-30 | -$18.30M 10-Q · filed 2025-11-04 | -$16.80M derived: sum of 2 quarters · filed 2025-11-04 | -$11.40M 10-Q · filed 2025-11-04 | -$19.30M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $1.50M 10-Q · filed 2025-08-05 | $6.90M 10-Q · filed 2025-08-05 | -$1.00M derived: sum of 3 quarters · filed 2026-02-13 | $700.00K derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $5.40M 10-Q · filed 2025-05-06 | -$2.50M derived: sum of 2 quarters · filed 2026-02-13 | -$800.00K derived: sum of 3 quarters · filed 2026-02-13 | $3.50M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | -$7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$6.20M derived: sum of 2 quarters · filed 2026-02-13 | -$1.90M derived: sum of 3 quarters · filed 2026-02-13 | -$2.70M 10-K · filed 2026-02-13 |
| 2023-09-30 | $1.70M 10-Q · filed 2024-11-05 | $6.00M derived: sum of 2 quarters · filed 2024-11-05 | $5.20M 10-Q · filed 2024-11-05 | $5.20M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $4.30M 10-Q · filed 2024-08-02 | $3.50M 10-Q · filed 2024-08-02 | $3.50M derived: sum of 3 quarters · filed 2025-02-13 | $3.50M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$800.00K 10-Q · filed 2024-05-07 | -$800.00K derived: sum of 2 quarters · filed 2025-02-13 | -$800.00K derived: sum of 3 quarters · filed 2025-02-13 | -$800.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $0.00 derived: sum of 3 quarters · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |